CARN common mistakes
CARN · Understand the traps and how to avoid them.
Choosing a treatment recommendation based on the client's stated preference or the most intensive option available, rather than matching the assessed severity to the correct ASAM level of care (e.g., recommending residential for a mild opioid use disorder or outpatient for severe withdrawal risk).
Candidates conflate 'more care is safer' with correct placement, or anchor on the dramatic-sounding option; they skip the dimensional assessment (withdrawal risk, medical/psychiatric severity, readiness, relapse potential, recovery environment) that determines level.
What to do instead
For every level-of-care item, explicitly score the six ASAM dimensions in scratch notes, then select the least restrictive level that safely meets the highest-severity dimension. Practice mapping each dimension to a level before answering.
Selecting a medication-assisted treatment agent without checking the client's current substance use, hepatic status, or whether the goal is withdrawal management vs. maintenance (e.g., starting naltrexone during active opioid use, or methadone/buprenorphine in a patient with severe liver failure without adjustment).
Candidates memorize drug classes but not the contraindications and induction rules that distinguish them; they answer the 'which drug' question without the 'which patient' filter.
What to do instead
Build a one-page matrix of MAT agents (agonist/partial agonist/antagonist), induction requirements, contraindications, and monitoring. Before answering, identify the patient's active substances, organ function, and treatment goal, then eliminate options that violate any of these.
Confusing tolerance, dependence, and addiction, or labeling physiologic withdrawal as evidence of a substance use disorder, when the DSM-5-TR criteria do not count tolerance/withdrawal toward the diagnosis when the substance is taken as prescribed.
Everyday and media usage blur these terms; candidates apply the colloquial definition of 'addiction' to a patient on long-term prescribed opioids or benzodiazepines.
What to do instead
Drill the DSM-5-TR criteria and the explicit exception for appropriately prescribed medications. On any diagnostic item, count criteria systematically and check whether tolerance/withdrawal are excluded by the prescribed-use rule.
Managing withdrawal with the wrong agent or timeline (e.g., using opioid agonists for stimulant withdrawal, or failing to recognize that alcohol/benzodiazepine withdrawal can be life-threatening and requires benzodiazepines and possible medical detox rather than supportive care alone).
Candidates treat all withdrawal as 'flu-like and self-limiting' and miss the risk stratification that makes alcohol and sedative-hypnotic withdrawal medically dangerous while opioid withdrawal is rarely fatal.
What to do instead
Memorize a withdrawal table by substance: danger level, timeline, first-line agent, and monitoring. Flag any alcohol/benzodiazepine withdrawal item as high-risk and check for seizure/delirium risk before choosing supportive-only answers.
Breaking confidentiality or mishandling 42 CFR Part 2 vs. HIPAA distinctions-e.g., disclosing SUD treatment records to family or a primary care provider without a proper written consent, or assuming HIPAA alone governs SUD records.
Candidates apply general HIPAA rules uniformly and forget that federally assisted SUD programs are governed by stricter Part 2 consent requirements and re-disclosure limits.
What to do instead
Study the Part 2 consent elements (who, what, to whom, purpose, expiration, revocation) and the exceptions (medical emergency, court order, audit). On ethics/legal items, first ask 'is this a Part 2 program?' then apply the stricter rule.
Missing co-occurring disorders by attributing psychiatric symptoms entirely to substance use (or vice versa), and failing to integrate mental health treatment with SUD treatment.
Candidates default to 'it's just the drugs' or 'it's just depression,' and the exam rewards integrated, concurrent treatment and recognition that symptoms may persist after detoxification.
What to do instead
For every co-occurring item, ask whether symptoms persist beyond expected withdrawal/early abstinence windows. Choose integrated treatment over sequential or parallel models unless the stem specifies a reason otherwise.
Selecting confrontation-based or purely educational interventions for a client in precontemplation, rather than stage-matched motivational strategies, and misclassifying the client's stage of change.
Candidates answer with the 'tough love' option that feels decisive, or skip identifying the stage before choosing an intervention; they also confuse action with maintenance.
What to do instead
First label the stage of change from the stem's language (no problem = precontemplation; ambivalent = contemplation; recent change = action). Then pick the process matched to that stage (consciousness raising, self-reevaluation, stimulus control, etc.).
Treating relapse as a single failure event rather than a process with warning signs, and recommending discharge or punishment instead of re-assessment and adjustment of the treatment plan.
Candidates hold a moral model of relapse and choose the punitive or termination option, or they ignore the lapse-to-relapse distinction and the role of high-risk situations.
What to do instead
On relapse items, identify the stage (emotional, mental, physical), reinforce that lapse ≠ relapse, and select re-engagement/re-assessment over discharge. Memorize relapse prevention skills (coping, high-risk situation planning, lifestyle balance).
Misapplying screening vs. assessment vs. diagnosis-using a brief screening tool (e.g., AUDIT-C, DAST) as if it were diagnostic, or skipping screening before assessment.
Candidates blur the purpose of instruments; they pick the 'most thorough' tool for a screening question or a single cutoff score for a diagnosis.
What to do instead
Memorize the function of each instrument tier: screening (brief, identifies risk), assessment (comprehensive, guides treatment planning), diagnosis (DSM-5-TR criteria applied by qualified clinician). Match the tool to the stem's stated purpose.
Ignoring harm reduction and prevention framing-e.g., rejecting naloxone distribution, syringe services, or fentanyl test strips because they seem to 'enable' use, and misapplying primary/secondary/tertiary prevention categories.
Candidates bring personal values or a strict abstinence-only lens and select the option that withholds harm-reduction tools, or they mislabel a prevention level.
What to do instead
Adopt the evidence-based stance that harm reduction reduces morbidity/mortality without requiring abstinence. Classify prevention by target population (universal/selected/indicated) and by level (primary/secondary/tertiary), then choose the option consistent with public health evidence.